Skylands Capital LLC Purchases New Stake in Thermo Fisher Scientific Inc. $TMO

Skylands Capital LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 3,825 shares of the medical research company’s stock, valued at approximately $1,880,000.

Other institutional investors have also made changes to their positions in the company. J. Stern & Co. LLP grew its position in shares of Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after buying an additional 31,455,105 shares during the period. Norges Bank acquired a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $3,072,744,000. Auto Owners Insurance Co increased its stake in Thermo Fisher Scientific by 57,845.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock valued at $1,406,844,000 after purchasing an additional 2,423,706 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in Thermo Fisher Scientific by 2,183.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company’s stock worth $770,000,000 after buying an additional 1,270,643 shares during the period. Finally, Wellington Management Group LLP grew its stake in Thermo Fisher Scientific by 88.9% in the third quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company’s stock valued at $1,309,292,000 after acquiring an additional 1,270,191 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on TMO. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their price objective for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $605.09.

Thermo Fisher Scientific Stock Up 1.5%

NYSE:TMO opened at $513.54 on Friday. The firm has a market capitalization of $190.84 billion, a price-to-earnings ratio of 28.23, a price-to-earnings-growth ratio of 2.27 and a beta of 0.88. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $401.45 and a twelve month high of $643.99. The stock’s 50 day moving average price is $474.08 and its two-hundred day moving average price is $520.19.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. The business had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the business earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.